Myosin Binding Protein H Research Articles

Functional role of myosin-binding protein H in thick filaments of developing vertebrate fast-twitch skeletal muscle.

Myosin-binding protein H (MyBP-H) is a component of the vertebrate skeletal muscle sarcomere with sequence and domain homology to myosin-binding protein C (MyBP-C). Whereas skeletal muscle isoforms of MyBP-C (fMyBP-C, sMyBP-C) modulate muscle contractility via interactions with actin thin filaments and myosin motors within the muscle sarcomere "C-zone," MyBP-H has no known function. This is in part due to MyBP-H having limited expression in adult fast-twitch muscle and no known involvement in muscle disease. Quantitative proteomics reported here reveal that MyBP-H is highly expressed in prenatal rat fast-twitch muscles and larval zebrafish, suggesting a conserved role in muscle development and prompting studies to define its function. We take advantage of the genetic control of the zebrafish model and a combination of structural, functional, and biophysical techniques to interrogate the role of MyBP-H. Transgenic, FLAG-tagged MyBP-H or fMyBP-C both localize to the C-zones in larval myofibers, whereas genetic depletion of endogenous MyBP-H or fMyBP-C leads to increased accumulation of the other, suggesting competition for C-zone binding sites. Does MyBP-H modulate contractility in the C-zone? Globular domains critical to MyBP-C's modulatory functions are absent from MyBP-H, suggesting that MyBP-H may be functionally silent. However, our results suggest an active role. In vitro motility experiments indicate MyBP-H shares MyBP-C's capacity as a molecular "brake." These results provide new insights and raise questions about the role of the C-zone during muscle development.

Abstract Or107: MyBP-HL nonsense mutations fail in sarcomere incorporation leads to modifications in myocyte contraction trough calcium modifications.

Introduction: Heart function depends on the cardiomyocyte contractile apparatus and proper sarcomere protein expression. Mutations in sarcomere genes cause inherited forms of cardiomyopathy and arrhythmias, including atrial fibrillation. AF is the most common cardiac arrhythmia and is associated with ischemic stroke, heart failure, and substantial morbidity and mortality. Recently, our group described a novel sarcomere component, myosin binding protein-H like (MyBP-HL), that is mainly expressed in the cardiac atria. MyBP-HL is composed of two immunoglobulin domains and one fibronectin domain, with homology to last three C-terminal domains of cardiac myosin binding protein-C (cMyBP-C). cMyBP-C nonsense mutations prevent his incorporation into the sarcomere. C-MyBP-C truncated peptides are identified by cells as poisoning peptides, and they are rapidly degraded. cMyBP-C nonsense mutations are causative of hypertrophic cardiomyopathy (HCM). The MyBP-HL Arg255stop variant has been described in humans and has been linked to ventricular conduction system abnormalities, atrial enlargement, dilated cardiomyopathy, and atrial and ventricular arrhythmias. The gnomAD database reports 9 nonsense mutations for MYBPHL in humans (Gln29, Trp54, Arg113, Tyr123, Trp158, Trp192, Lys250, Arg255, and Tyr307). Hypothesis: MYBPHL nonsense mutations fail to incorporate into the sarcomere will lead to contractile disfunction. Results: We demonstrated that MyBP-HL overexpression showed to be able to incorporate in a similar pattern to cMyBP-C C-zone doublets. Nevertheless, nonsense mutations disrupt normal sarcomere localization. MyBP-HL nonsense mutations promote an increase in contraction amplitude and slower relaxation kinetics. Also, we observed an increase in sarcomere length. Similarly, MyBP-HL nonsense mutations lead to increase in amplitude peak of calcium transients, and reduction in velocity to maximal calcium peak. In accordance with calcium modifications, we observed through mass spectrometry an increase in calpain 6 abundance promoted by MyBP-HL nonsense mutations. Conclusion: Based on these data, we demonstrated that MYBPHL nonsense mutations prevent MyBP-HL incorporation into the thick filament. The failure of MyBP-HL truncating peptides to incorporate into the sarcomere leads to a deficiencies in myocytes contraction patterns, changes in calcium patterns and increase in degradation proteins abundance, which are related to AF prevalence.

Abstract P1023: Nonsense Mutations In Atrial Myofilament Regulatory Protein MyBP-HL Are Subject To Proteolytic Degradation And Loss Of Functional Protein

Background: Myosin binding protein-H like (MyBP-HL) is a recently identified atrial myofilament protein encoded by the gene MYBPHL. The Arg255Stop mutant has been linked to atrial enlargement, atrial fibrillation, and dilated cardiomyopathy. Deletion of MYBPHL in mice recapitulates this human phenotype. MyBP-HL is composed of two Immunoglobulin domains (Ig) and one Fibronectin domain (FnIII), like the structure and sequence of the last three C-terminal domains (C8-C9-C10) of cardiac myosin binding protein-C (cMyBP-C). cMyBP-C nonsense mutations fail in myofilament incorporation and result in a rapid degradation of the truncated protein and are a major cause of hypertrophic cardiomyopathy. There are 9 premature stop mutations in MYBPHL identified in humans (Gln29, Trp54, Arg113, Tyr123, Trp158, Trp192, Lys250, Arg255, and Tyr307). Hypothesis: We hypothesize that MYBPHL nonsense mutations will share a common mechanism that leads to MyBP-HL failing to integrate into the sarcomere, resulting in truncated MyBP-HL degradation and loss myofilament incorporation. Results: We demonstrate heterologous expression of MyBP-HL in neonatal rat cardiomyocytes can incorporate in a similar sarcomere pattern as cMyBP-C. Expression of the nine nonsense mutations do not localize into the sarcomere. Neonatal rat cardiomyocytes transfected with MyBP-HL constructs were treated with proteasome and/or calpain inhibitors. We observed that wild-type MyBP-HL and MyBP-HL truncating mutations are degraded mainly by the proteasome, although we also identified a significant calpain involvement in MyBP-HL degradation. Shorter MyBP-HL truncated peptides are degraded as a poisoning peptides, but longer peptides are not degraded. Conclusion: Based on these data, we demonstrated that MYBPHL nonsense mutations prevent MyBP-HL incorporation into the thick filament as are subject to degradation. The differential expression of short vs. long truncating MyBP-HL mutants suggest a differential pathogenic mechanism for subsets of these mutations.

Myosin binding protein h dominates the "c-zone" in ultrafast swimming muscles of developing zebrafish.

The ‘C-zone’ of mature vertebrate skeletal muscle sarcomeres is characterized by the presence of Myosin-Binding Protein C (MyBP-C), which ‘tunes’ contractility via its N-terminal domain interactions with the myosin head region and/or the thin filament. The ultrafast swimming muscles of zebrafish larvae are a perfect model system to define MyBP-C isoform function, due to tractable genetics and easily characterized muscle mechanics. However, liquid chromatography mass spectrometry shows 5-day-old larval muscle expresses MyBP-C at only ∼5% of the ∼1:10 molar ratio with myosin heavy chain (MYH) typically associated with full C-zone occupancy, while a little-studied MyBP-C paralog, Myosin-Binding Protein H (MyBP-H) comprises the remaining ∼95%. MyBP-H is homologous to MyBP-C's C terminus, which binds to the myosin thick filament backbone, but it lacks analagous N-terminal regulatory domains, which are critical to MyBP-C's slowing of muscle shortening. Therefore, the presence of MyBP-H may underlie the extreme contractile speed of larval muscle (>30 lengths/s), and/or indicate its involvement in muscle development. To define MyBP-H's potential roles, we first imaged its sarcomeric localization in larvae expressing transgenic, FLAG-tagged MyBP-H. Immunofluorescence revealed characteristic fluorescence doublets at the sarcomere center, indicating MyBP-H binds throughout the C-zone. Interestingly, MyBP-H-null mutants engineered using CRISPR/Cas9 appear to develop normally, suggesting the developmental impact of MyBP-H may be subtle. Preliminary mechanical studies of MyBP-H-null larval muscles showed no change in twitch kinetics, tetanic force, or the Force:Velocity relationship, which might be expected, given MyBP-C content increases only minimally (From ∼5% to ∼10% of full C-zone occupancy). Although the role of MyBP-H in development remains an enigma, physiologically stressing the larvae may reveal MyBP-H's function. At a minimum, the MyBP-H null larvae provide a clean slate to repopulate the C-zone using transgenically expressed human or disease-causing MyBP-C isoforms.

Abstract GS101: Myosin Binding Protein H-like Competes With Cardiac Myosin Binding Protein-c To Prolong Atrial Contraction

Myosin binding protein-H like (MyBP-HL) has recently been identified as a novel component of myofilaments in the cardiac atria. Loss of MyBP-HL is associated with dilated cardiomyopathy and arrhythmia in humans and mice. MyBP-HL is highly homologous to cardiac myosin binding protein-C (cMyBP-C), which has been studied in the context of genetic cardiomyopathy. Prior work using mouse atrial tissue lysates established MyBP-HL and cMyBP-C bind competitively and maintain a stoichiometric ratio compared to myosin heavy chain. We now confirm this competitive binding using neonatal rat ventricular cardiomyocytes (NRVMs) transfected with mouse Mybphl . Using confocal microscopy with internal controls, we found a linear, inverse relationshib between myosin binding protein levels with NRVMs with high levels of MyBP-HL expression showing a reduction in cMyBP-C levels compared to untransfected NRVMs that only express cMyBP-C. While we show that these two myosin binding proteins bind comparatively with each other, the functional consequences are unclear. We performed force-calcium measurements of permeabilized single atrial cardiomyocytes and found that loss of MyBP-HL does not significantly alter the calcium sensitivity of force development, or the specific force generated by isometric contraction. Because cMyBP-C is a known regulator of crossbridge sliding velocity, we evaluated contraction and relaxation kinetics of Mybphl single-myofibrils from WT and Mybphl homozygous null mice. Atrial myofibrils lacking Mybphl showed a significantly faster rate and shorter duration of their linear phase of relaxation, which is governed by the off-rate of myosin from actin. This suggests that extra cMyBP-C in the atria can hasten myofibril relaxation. In healthy atria with MyBP-HL replacing approximately half the cMyBP-C, the slow phase of relaxation is prolonged. While the physiological importance of this is not explored, it provides a mechanism by which loss of function mutations in MYBPHL cause contractile dysfunction.

High myosin binding protein H expression predicts poor prognosis in glioma patients

Glioma is the most common and fatal primary brain tumor in humans. Myosin binding protein H (MYBPH), which was first identified as an important myofibrillar constituent of vertebrate skeletal and cardiac muscles, reduces cell motility and metastasis. However, its role in gliomas remains unclear. We evaluated the expression of MYBPH in glioma using Gene Expression Profiling Interactive Analysis (http://gepia.cancer-pku.cn/) and Chinese Glioma Genome Atlas (https://www.cgga.org.cn/). The results showed that MYBPH was highly expressed in glioma tissues. Moreover, MYBPH expression was significantly associated with high tumor aggressiveness and poor outcomes in glioma patients. Mechanistically, the results suggested that MYBPH might promote tumor progression by improving tumor invasion and migration. Our results establish MYBPH as an important prognostic biomarker that could be considered a potential epigenetic and immunotherapeutic target for treatment. We showed that MYBPH is a novel biomarker that is variably expressed in glioblastoma (GBM). The association of high MYBPH expression with poor prognosis in newly diagnosed GBM patients and increased expression in recurrent GBM is indicative of its role in tumor aggressiveness.

MYBPH inhibits vascular smooth muscle cell migration and attenuates neointimal hyperplasia in a rat carotid balloon-injury model

Vascular smooth muscle cell (VSMC) migration is implicated in restenosis. Myosin binding protein H (MYBPH) is capable of reducing cell motility and metastasis. In this study, we sought to determine whether MYBPH is involved in VSMC migration and neointima formation in response to vascular injury. To determine the expression of MYBPH in injured artery, we used a standard rat carotid artery balloon-injury model. In vivo studies have demonstrated that MYBPH is upregulated after vascular injury. VSMCs treated with platelet-derived growth factor (PDGF)-BB displayed increased MYBPH mRNA and protein levels. PDGF-induced VSMC migration was inhibited by adenovirus-mediated expression of MYBPH whereas it was enhanced by small interfering RNA knockdown of MYBPH. The activation of ROCK1 was repressed by MYBPH. Luminal delivery of MYBPH adenovirus to carotid arteries decreased neointimal hyperplasia in vivo. MYBPH may, therefore, serve as a novel therapeutic target for postangioplasty restenosis.

MYBPH acts as modifier of cardiac hypertrophy in hypertrophic cardiomyopathy (HCM) patients.

Left ventricular hypertrophy is a risk factor for cardiovascular morbidity and mortality. Hypertrophic cardiomyopathy (HCM) is considered a model disease to study causal molecular factors underlying isolated cardiac hypertrophy. However, HCM manifests with various clinical symptoms, even in families bearing the same genetic defects, suggesting that additional factors contribute to hypertrophy. The gene encoding the cardiac myosin binding protein C (cMYBPC) is one of the most frequently implicated genes in HCM. Recently another myosin binding protein, myosin binding protein H (MYBPH) was shown to function in concert with cMYBPC in regulating cardiomyocyte contraction. Given the similarity in sequence, structure and the critical role MYBPH plays in sarcomere contraction, we proposed that MYBPH may be involved in HCM pathogenesis. Family-based genetic association analysis was employed to investigate the contribution of MYBPH in modifying hypertrophy. Seven single nucleotide polymorphisms and haplotypes in MYBPH were investigated for hypertrophy modifying effects in 388 individuals (27 families), in which three unique South African HCM-causing founder mutations (p.R403W and pA797T in β-myosin heavy chain gene (MYH7) and p.R92W in the cardiac troponin T gene (TNNT2)) segregate. We observed a significant association between rs2250509 and hypertrophy traits in the p.A797T MYH7 mutation group. Additionally, haplotype GGTACTT significantly affected hypertrophy within the same mutation group. MYBPH was for the first time assessed as a candidate hypertrophy modifying gene. We identified a novel association between MYBPH and hypertrophy traits in HCM patients carrying the p.A797T MYH7 mutation, suggesting that variation in MYBPH can modulate the severity of hypertrophy in HCM.

Ascribing novel functions to the sarcomeric protein, myosin binding protein H (MyBPH) in cardiac sarcomere contraction

Myosin binding protein H (MyBPH) is a protein of unknown function, which shares sequence and structural similarities with myosin binding protein C (cMyBPC), a protein frequently implicated in hypertrophic cardiomyopathy (HCM). Given the similarity between cMyBPC and MyBPH, we proposed that MyBPH, like cMyBPC, could be involved in HCM pathogenesis and we therefore sought to determine its function. We identified MyBPH-interacting proteins by using yeast two-hybrid (Y2H) analysis. The role of MyBPH and cMyBPC in cardiac cell contractility was analysed by measuring the planar cell surface area of differentiated H9c2 rat cardiomyocytes in response to β-adrenergic stress after siRNA knockdown of MyBPH and cMyBPC. Individual knockdown of either protein had no effect on cardiac contractility, while concurrent knockdowns reduced cardiac contractility. These proteins therefore functionally compensate for one another and are critical for cardiac contractility. We further show that both proteins co-localise with the autophagosomal membrane protein LC3, suggesting that both proteins are involved in autophagosomal membrane maturation processes. The results of this study ascribe novel functions to MyBPH, which may contribute to our understanding of its role in the sarcomere. This study provides evidence for a potential role of MyBPH in HCM, which warrants further investigation.

Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients

Amyotrophic lateral sclerosis (ALS) is a severe and fatal neurodegenerative disease of still unknown pathogenesis. Recent findings suggest that the skeletal muscle may play an active pathogenetic role. To investigate ALS's pathogenesis and to seek diagnostic markers, we analyzed skeletal muscle biopsies with the differential expression proteomic approach. We studied skeletal muscle biopsies from healthy controls (CN), sporadic ALS (sALS), motor neuropathies (MN) and myopathies (M). Pre-eminently among several differentially expressed proteins, Myosin binding protein H (MyBP-H) expression in ALS samples was anomalously high. MyBP-H is a component of the thick filaments of the skeletal muscle and has strong affinity for myosin, but its function is still unclear. High MyBP-H expression level was associated with abnormal expression of Rho kinase 2 (ROCK2), LIM domain kinase 1 (LIMK1) and cofilin2, that might affect the actin–myosin interaction. We propose that MyBP-H expression level serves, as a putative biomarker in the skeletal muscle, to discriminate ALS from motor neuropathies, and that it signals the onset of dysregulation in actin–myosin interaction; this in turn might contribute to the pathogenesis of ALS.

MYBPH inhibits NM IIA assembly via direct interaction with NMHC IIA and reduces cell motility

Actomyosin filament assembly is a critical step in tumor cell migration. We previously found that myosin binding protein H (MYBPH) is directly transactivated by the TTF-1 lineage-survival oncogene in lung adenocarcinomas and inhibits phosphorylation of the myosin regulatory light chain (RLC) of non-muscle myosin IIA (NM IIA) via direct interaction with Rho kinase 1 (ROCK1). Here, we report that MYBPH also directly interacts with an additional molecule, non-muscle myosin heavy chain IIA (NMHC IIA), which was found to occur between MYBPH and the rod portion of NMHC IIA. MYBPH inhibited NMHC IIA assembly and reduced cell motility. Conversely, siMYBPH-induced increased motility was partially, yet significantly, suppressed by blebbistatin, a non-muscle myosin II inhibitor, while more profound effects were attained by combined treatment with siROCK1 and blebbistatin. Electron microscopy observations showed well-ordered paracrystals of NMHC IIA reflecting an assembled state, which were significantly less frequently observed in the presence of MYBPH. Furthermore, an in vitro sedimentation assay showed that a greater amount of NMHC IIA was in an unassembled state in the presence of MYBPH. Interestingly, treatment with a ROCK inhibitor that impairs transition of NM IIA from an assembly-incompetent to assembly-competent state reduced the interaction between MYBPH and NMHC IIA, suggesting that MYBPH has higher affinity to assembly-competent NM IIA. These results suggest that MYBPH inhibits RLC and NMHC IIA, independent components of NM IIA, and negatively regulates actomyosin organization at 2 distinct steps, resulting in firm inhibition of NM IIA assembly.

Introducing a series of topical special issues of the Journal of Muscle Research and Cell Motility

The Journal of Muscle Research aims to serve its readers not only by publishing original studies in muscle and motility structure and function but also by informing readers of the state of the art in muscle research and cell motility and to promote debate. This issue of the Journal of Muscle Research and Cell Motility is the first of a series of topical special issues that combine original research with review articles related to a specific subject that we plan to publish once or twice a year. Further topical issues are being planned and we would welcome ideas for the themes to be covered in future issues. In this issue, articles are devoted to cardiac myosinbinding protein-C. When C-protein, or myosin-binding protein-C (MyBP-C) was discovered in skeletal muscle in the early 1970s by Gerald Offer (Offer 1972; Offer et al. 1973), MyBP-C was thought to be merely a structural protein component of the thick filament. Interest in the functions of MyBP-C were galvanised when it was found that the cardiac isoform, encoded by the MYBPC3 gene on chromosome 11, was mutated in cases of hereditary hypertrophic cardiomyopathy (HCM) (Bonne et al. 1995; Watkins et al. 1995). By now, mutations in MYBPC3 are the second-most frequently identified mutations that cause HCM (Schlossarek et al. 2011), with carriers of a specific pathogenic mutation amounting up to 4 % of the population of Indian descent (Dhandapany et al. 2009). It has become clear that MyBP-C must play important roles in both the regulation of contractility and as the assembly of muscle myofibrils. MyBP-C is transcribed from three related genes (MYBPC1-3), which encode the slow, fast and cardiac isoforms. Like many other myofibrilassociated structural proteins, MyBP-C is composed of a series of hundred-residue domains of the intracellular immunoglobulin and fibronectin families—10–11 in the case of MyBP-C (Furst and Gautel 1995; Otey et al. 2009). This molecular architecture is shared with the small MyBPC homologue, myosin-binding protein-H (Vaughan et al. 1993) and other myofibrillar proteins like myopalladin, myotilin, the myomesin isogenes and the giant scaffold and signalling proteins titin and obscurin (KontrogianniKonstantopoulos et al. 2009). Earlier work by the laboratories of Gerald Offer, Carl Moos, Roger Starr, Rick Moss, Polly Hofmann, Criss Hartzell and others had implicated MyBP-C in contraction regulation by interactions with actin or myosin filament components, possibly dynamically modulated by phosphorylation by cAMP and calcium/calmodulin dependent protein kinases in the case of the cardiac isoform (see articles in this issue for a review of the literature). The elucidation of the primary structure of both skeletal and cardiac MyBP-C isoforms pinpointed these phosphorylation sites to the N-terminal region within a sequence distinct from the immunoglobulin or fibronectin-like domains that form the remainder of the protein (Einheber and Fischman 1990; Furst et al. 1992; Gautel et al. 1995). This MyBP-C motif has since been implicated as the major domain involved in contraction regulation by interactions that have been localised to both the actin and myosin S. B. Marston NHLI, Myocardial Function, Imperial College London, Imperial Centre for Translational and Experimental Medicine, London W12 0NN, UK e-mail: S.marston@imperial.ac.uk

MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis

Cell migration driven by actomyosin filament assembly is a critical step in tumour invasion and metastasis. Herein, we report identification of myosin binding protein H (MYBPH) as a transcriptional target of TTF-1 (also known as NKX2-1 and TITF1), a master regulator of lung development that also plays a role as a lineage-survival oncogene in lung adenocarcinoma development. MYBPH inhibited assembly competence-conferring phosphorylation of the myosin regulatory light chain (RLC) as well as activating phosphorylation of LIM domain kinase (LIMK), unexpectedly through its direct physical interaction with Rho kinase 1 (ROCK1) rather than with RLC. Consequently, MYBPH inhibited ROCK1 and negatively regulated actomyosin organization, which in turn reduced single cell motility and increased collective cell migration, resulting in decreased cancer invasion and metastasis. Finally, we also show that MYBPH is epigenetically inactivated by promoter DNA methylation in a fraction of TTF-1-positive lung adenocarcinomas, which appears to be in accordance with its deleterious functions in lung adenocarcinoma invasion and metastasis, as well as with the paradoxical association of TTF-1 expression with favourable prognosis in lung adenocarcinoma patients.

Abstract LB-360: MYBPH, a novel transcriptional target of TTF-1/NKX2–1, inhibits ROCK1 and actomyosin assembly, and reduces cell motility and tumor metastasis

Abstract Lung cancer is the leading cause of cancer death in most economically developed countries, with lung adenocarcinoma the most prevalent form. The vast majority of lung cancer-related deaths is caused by invasion and metastasis, thus it is crucially important to elucidate the underlying mechanisms. We previously reported that lung adenocarcinomas are addicted to sustained expression of TTF-1 (also know as NKX2–1 and TITF1), a lineage-specific transcription factor required for branching morphogenesis and physiological lung functions, while others subsequently reached similar conclusions in studies that used genome-wide searches for focal genomic aberrations in lung adenocarcinomas. However, TTF-1/NKX2–1 expression is paradoxically known to be associated with favourable prognosis in lung adenocarcinoma cases. Emerging evidence indicates that non-muscle myosin II (NM II) members, especially NM IIA, are crucially involved in cancer cell migration, invasion, and metastasis via bivalent binding to actin filaments. Rho kinase 1 (ROCK1), a downstream effecter of RhoA, has been shown to be a major positive regulator of that process, which is thought to be executed through phosphorylation of myosin regulatory light chain (RLC) and subsequent unfolding of NM IIA into an assembly competent form capable of NM IIA dimer formation. In addition, ROCK1 phosphorylates LIM domain kinase (LIMK) and stabilizes actin filaments through inactivation of the actin-depolymerising factor cofilin. However, how actomyosin organization in non-muscle cells is regulated to counter-balance the positive regulatory function of ROCK1 remains to be elucidated. Herein, we report identification of myosin binding protein H (MYBPH) as a transcriptional target of TTF-1/NKX2–1, a lineage-survival oncogene in lung adenocarcinoma. MYBPH inhibits assembly competence-conferring phosphorylation of RLC as well as activating phosphorylation of LIMK. These are unexpectedly implemented through direct physical interaction of MYBPH with ROCK1 rather than with RLC, leading to inhibition of the ROCK1 kinase activity. In addition, MYBPH is shown to directly bind with non-muscle myosin heavy chain IIA (NMHC IIA), resulting in inhibition of NMHC IIA assembly. Thus, the present findings demonstrate that MYBPH plays multi-facetted roles in negative regulation of actomyosin organization, which we find results in reduction of cell motility, invasion, and metastasis. Finally, we also show that MYBPH is epigenetically inactivated by promoter DNA methylation in a fraction of lung adenocarcinomas abundantly expressing TTF-1/NKX2–1, which appears to be in accordance with its deleterious function for lung adenocarcinoma invasion and metastasis, as well as with the paradoxical association of TTF-1/NKX2–1 expression with favourable prognosis in lung adenocarcinoma patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-360. doi:10.1158/1538-7445.AM2011-LB-360

Long-term cultured human myotubes decrease contractile gene expression and regulate apoptosis-related genes

The present study examined time-dependent changes in the gene expression profile of long-term cultured human myotubes. Microarray transcriptional analysis was performed in a primary culture of differentiated myotubes from one subject over seven weeks. This analysis showed a main gradual fall in genes of the contractile apparatus, and a broad upregulation of genes involved in cell development and growth, followed by stress response and signal transduction. Glucose metabolism was also monitored, but no significant alterations in glucose uptake, oxidation or glycogen storage were observed. Mitochondrial membrane potential, or the amount of membrane lipid peroxides, remained similarly unchanged, nor was lactate dehydrogenase leakage observed. Time-dependent changes in eight genes were validated by real-time RT-PCR in primary cultured myotubes from four subjects, of similar age and isolated after equivalent replication cycles in vitro and differentiated over seven weeks. Insulin-like growth factor-binding protein 2 (IGFBP2), a modulator of the IGF signal, was upregulated. The antiapoptotic gene heat-shock 70-kd protein 2 (HSPA2) was induced, whereas the proapoptotic tumor necrosis factor receptor superfamily, member 25 (WSL-1) was suppressed. A decline in the muscle-specific gene M-cadherin and contraction genes, such as slow-twitch troponin I (TNNI1) and myosin heavy chain 2 (MYH2), myosin light chain 1 (MYL1) and myosin-binding protein H (MYBPH), which are expressed in adult fast-twitch muscle, was shown. In summary, these data demonstrate extensive downregulation of contractile genes and modulation of apoptosis-related genes, in favour of cell survival, during maintenance of cultured human myotubes.

Impact of post-synaptic block of neuromuscular transmission, muscle unloading and mechanical ventilation on skeletal muscle protein and mRNA expression

To analyse mechanisms of muscle wasting in intensive care unit patients, we developed an experimental model where rats were pharmacologically paralysed by post-synaptic block of neuromuscular transmission (NMB) and mechanically ventilated for 9+/-2 days. Specific interest was focused on the effects on protein and mRNA expression of sarcomeric proteins, i.e., myosin heavy chain (MyHC), actin, myosin-binding protein C (MyBP-C) and myosin-binding protein H (MyBP-H) in fast- and slow-twitch limb, respiratory and masticatory muscles. Muscle-specific differences were observed in response to NMB at both the protein and mRNA levels. At the protein level, a decreased MyHC-to-actin ratio was observed in all muscles excluding the diaphragm, whereas at the mRNA level a decreased expression of the dominating MyHC isoform(s) was observed in the hind limb and intercostal muscles, but not in the diaphragm and masseter muscles. MyBP-C mRNA expression was decreased in the limb muscles, but it otherwise remained unaffected. MyBP-H conversely increased in all muscles. Furthermore, we found myofibrillar protein and mRNA expression to be affected differently when comparing NMB animals with peripherally denervated (DEN) ambulatory rats. We report that NMB has both a larger and different impact on muscle, at the protein and mRNA levels, than DEN has.

Skeletal muscle heavy-chain polypeptide 3 and myosin binding protein H in the pubococcygeus muscle in patients with and without pelvic organ prolapse

The purpose of this study was to compare gene expression of skeletal muscle heavy-chain polypeptide 3 (MYH3) and myosin binding protein H (MyBP-H) in the pubococcygeus muscle of patients with pelvic organ prolapse and controls. Genes previously identified by microarray genechip analysis of pubococcygeus muscle biopsies were examined using real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) analysis. Specimens were obtained from 17 patients with stage III or IV pelvic organ prolapse and 23 controls with minimal to no prolapse. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene. Samples and controls were run in triplicate in separate wells, and the levels of gene expression were analyzed quantitatively using the comparative critical threshold (Ct) method. Differences in gene expression were analyzed using Wilcoxon rank-sum testing. Significant differences in gene expression were observed between patients with prolapse and controls for both genes. Skeletal muscle myosin heavy-chain polypeptide 3 was 6.5 times underexpressed in patients with pelvic organ prolapse compared to controls (P = .028). Similarly, myosin binding protein H was 3.2 times underexpressed in patients with prolapse (P = .042). Overall, patients had a mean age of 62.4 +/- 6.5 years compared with controls with a mean age of 45.3 +/- 7.4 years (P < .001), so analysis was also performed on an age-matched subset of 8 patients and controls (mean ages of 58.1 +/- 5.4 years and 53.3 +/- 5.0 years, respectively, P = .02) with similar results. Prolapse patients in this subset were similar in parity and race to controls but had lower body mass index (23.2 vs 29.9, P = .04). MYH3 was 10.9 times underexpressed in patients with pelvic organ prolapse compared to controls (P = .027). MyBP-H was 10.4 times underexpressed in patients with prolapse (P = .036). These findings suggest that the differences between patients with advanced pelvic organ prolapse and controls may be related to differential gene expression of structural proteins related to myosin. Specifically, advanced pelvic organ prolapse may be related to down-regulation of skeletal muscle heavy-chain polypeptide 3 and myosin binding protein H.

Precise mapping of breakpoints in conserved synteny between human chromosome 1 and pig chromosomes 4, 6 and 9.

Previous comparative mapping suggested that at least five pig chromosomes (Sscr4, 6, 9, 10 and 14) share homology with human chromosome 1 (Hsap1). A significant quantitative trait loci (QTL) for fat deposition has been identified on Sscr4 that appears to be near the junction region between Sscr4 and Sscr9 relative to Hsap1. It is of interest to define the boundaries of conserved synteny between pig chromosomes and Hsap1 to use human map information to identify putative comparative positional candidates for this QTL. Eleven genes, including Janus kinase 1 (JAK1), Prostaglandin E receptor3 (PTGER3), urate oxidase (UOX), coagulation factor 3 (F3), vascular cell adhesion molecule 1 (VCAM1), ribosomal protein L5 (RPL5), POU domain, class 2, transcription factor 1 (POU2F1), coagulation factor 5 (F5), Prostaglandin endoperoxide synthase-2 (PTGS2), myosin binding protein H (MYBPH) and Antithrombin III (SERPINC1), were selected to refine the boundaries of the blocks of conserved synteny between Hsap1 and pig chromosomes. Pig sequence tagged sites (STSs) were developed and used to physically map these 11 genes using a somatic cell hybrid panel. Eight loci have been mapped by using fluorescent in situ hybridization (FISH) to improve map resolution. Heterologous FISH was used to refine the location of VCAM1 on human chromosomes. In addition, human yeast artificial chromosomes (YACs) were mapped by heterologous FISH on pig metaphases to refine the boundaries of the regions of homology between Sscr4 and Sscr9 on Hsap1. Results from this study suggest the precise break in conserved synteny on Hsap1 corresponding to the Sscr4/6 and Sscr4/9 transitions are most likely on the Hsap1p22 and Hsap1q24-25 regions, respectively. Further, our data predict that Hsap1q21-24 is a candidate region for the backfat QTL localized to Sscr4.

Nucleotide and deduced amino acid sequences of rat myosin binding protein H (MyBP-H).

The complete nucleotide sequence of the cDNA clone encoding rat skeletal muscle myosin-binding protein H (MyBP-H) was determined and amino acid sequence was deduced from the nucleotide sequence (GenBank accession number AF077338). The full-length cDNA of 1782 base pairs(bp) contains a single open reading frame of 1454 bp encoding a rat MyBP-H protein of the predicted molecular mass 52.7 kDa and includes the common consensus 'CA__TG' protein binding motif. The cDNA sequence of rat MyBP-H show 92%, 84% and 41% homology with those of mouse, human and chicken, respectively. The protein contains tandem internal motifs array (-FN III-Ig C2-FN III-Ig C2-) in the C-terminal region which resembles to the immunoglobulin superfamily C2 and fibronectin type III motifs. The amino acid sequence of the C-terminal Ig C2 was highly conserved among MyBPs family and other thick filament binding proteins, suggesting that the C-terminal Ig C2 might play an important role in its function. All proteins belonging to MyBP-H member contains 'RKPS' sequence which is assumed to be cAMP- and cGMP-dependent protein kinase A phosphorylation site. Computer analysis of the primary sequence of rat MyBP-H predicted 11 protein kinase C (PKC) phosphorylation site, 7 casein kinase II (CK2) phosphorylation site and 4 N-myristoylation site.

Human Myosin-Binding Protein H (MyBP-H): Complete Primary Sequence, Genomic Organization, and Chromospinal Localization

Vertebrate striated muscle contains a set of myosin-associated proteins with discrete distributions in the A-band. Some of these proteins, including MyBP-H and MyBP-C, are characterized by a series of internal repeats (motifs) with homology to either the C2-set of the immunoglobulin superfamily or the fibronectin type III repeat. These repeats are predicted to be involved in protein--protein interactions within the myofibril. The cDNA sequence, the genomic organization, and the chromosomal localization of the human homologue of MyBP-H are presented. The 1.8-kb cDNA encodes a 52-kDa polypeptide containing two Ig-C2 and two type III repeats. The mRNA is expressed in a skeletal muscle-specific pattern. A 28-kb region of genomic sequence has been isolated that encompasses the 5′ and 3′ ends of the cDNA. This region includes 4.2 kb of upstream sequence with a potential promoter and 14 kb of downstream sequence containing the polyadenylation site. The chromosomal assignment was made by high resolution chromosomal in situ hybridization. This method maps the gene to chromosome 1q32.1. The repeat structure described previously in chicken MyBP-H and MyBP-C was also detected in human MyBP-H. The primary sequence of the C-terminal Ig-C2 motif and its predicted secondary structure have been extensively conserved in MyBP-H homologues and other members of the MyBP family. This Ig-C2 motif has been implicated in myosin binding.